Non-invasive Diagnosis of Focal Liver Lesions: an Individualized Approach

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2012 Oct 2

PMID 23023267

Citations 5

Authors

Wolfgang Schima

Claus Kolblinger

Ahmed Ba-Ssalamah

Affiliations

Soon will be listed here.

Abstract

Modern cross-sectional imaging with multidetector computed tomography (MDCT) or magnetic resonance imaging (MRI) often reveals small focal liver lesions, which puts pressure on the reporting radiologist to characterize these tiny lesions. On the other hand, in patients with underlying diffuse liver disease, such as cirrhosis or severe steatosis, the detection of focal liver lesions can be quite difficult. Strategies for optimal detection and characterization of focal liver lesions should be developed according to the clinical situation, the likelihood of malignant disease and the presence of underlying diffuse liver disease. The presence or absence of a clinical history of cancer determines the algorithm for further characterization: work-up with contrast-enhanced MRI, biopsy or follow-up. In patients with chronic liver disease, recent guidelines on the detection of hepatocellular carcinoma (HCC) favour the use of multiphasic MRI or MDCT, which allows confident diagnoses of HCC >1 cm. For lesions <1 cm in chronic liver disease, follow-up is recommended. In patients with moderate to severe steatosis, contrast-enhanced MDCT has low diagnostic yield for the detection of liver lesions; contrast-enhanced MRI is far superior. This review describes successful strategies for the detection and characterization of focal liver lesions in different clinical scenarios.

Citing Articles

Patterns and Clinico-Radiological Characteristics of Primary Liver Masses in Children Treated at a Tertiary Referral Hospital, in Ethiopia.

Ayllo M, Tamire A, Legas M, Arega G Pediatric Health Med Ther. 2023; 14:455-464.

PMID: 38074195 PMC: 10705446. DOI: 10.2147/PHMT.S433460.

Deep learning HASTE sequence compared with T2-weighted BLADE sequence for liver MRI at 3 Tesla: a qualitative and quantitative prospective study.

Wary P, Hossu G, Ambarki K, Nickel D, Arberet S, Oster J Eur Radiol. 2023; 33(10):6817-6827.

PMID: 37188883 DOI: 10.1007/s00330-023-09693-y.

Convolutional neural networks versus radiologists in characterization of small hypoattenuating hepatic nodules on CT: a critical diagnostic challenge in staging of colorectal carcinoma.

Khalili K, Lawlor R, Pourafkari M, Lu H, Tyrrell P, Kim T Sci Rep. 2020; 10(1):15248.

PMID: 32943654 PMC: 7499427. DOI: 10.1038/s41598-020-71364-5.

Quantitative evaluation of Gd-EOB-DTPA uptake in focal liver lesions by using T1 mapping: differences between hepatocellular carcinoma, hepatic focal nodular hyperplasia and cavernous hemangioma.

Peng Z, Li C, Chan T, Cai H, Luo Y, Dong Z Oncotarget. 2017; 8(39):65435-65444.

PMID: 29029443 PMC: 5630343. DOI: 10.18632/oncotarget.18918.

Imaging for suspected colorectal cancer in frail and elderly patients.

Bacigalupo L, Paparo F Tech Coloproctol. 2013; 18(2):125-7.

PMID: 23928712 DOI: 10.1007/s10151-013-1056-1.

References

Coenegrachts K, De Geeter F, Ter Beek L, Walgraeve N, Bipat S, Stoker J . Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol. 2008; 19(2):370-9. DOI: 10.1007/s00330-008-1163-y. View

Cascinu S, Falconi M, Valentini V, Jelic S . Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v55-8. DOI: 10.1093/annonc/mdq165. View

Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnu L, Zoli M . Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002; 97(3):734-44. DOI: 10.1111/j.1572-0241.2002.05557.x. View

Casali P, Blay J . Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v98-102. DOI: 10.1093/annonc/mdq208. View

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R . Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004; 126(4):1005-14. DOI: 10.1053/j.gastro.2003.12.049. View

Scharitzer M, Schima W, Schober E, Reimer P, Helmberger T, Holzknecht N . Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2005; 29(2):181-90. DOI: 10.1097/01.rct.0000156397.51640.a1. View

Niekel M, Bipat S, Stoker J . Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010; 257(3):674-84. DOI: 10.1148/radiol.10100729. View

Park M, Kim Y, Lee W, Lim H, Rhim H, Lee J . Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population. Eur Radiol. 2010; 20(10):2397-404. DOI: 10.1007/s00330-010-1810-y. View

Trinchet J, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H . Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011; 54(6):1987-97. DOI: 10.1002/hep.24545. View

10.

Stahl M, Budach W, Meyer H, Cervantes A . Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v46-9. DOI: 10.1093/annonc/mdq163. View

11.

Hwang S, Yu J, Kim K, Kim J, Chung J . Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr. 2008; 32(1):39-45. DOI: 10.1097/RCT.0b013e318064c76b. View

12.

Kinkel K, Lu Y, Both M, Warren R, Thoeni R . Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002; 224(3):748-56. DOI: 10.1148/radiol.2243011362. View

13.

Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A . Liver metastases of colorectal cancer: US, CT or MR?. Cancer Imaging. 2005; 5 Spec No A:S149-56. PMC: 1665297. DOI: 10.1102/1470-7330.2005.0035. View

14.

Khalil H, Patterson S, Panicek D . Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology. 2005; 235(3):872-8. DOI: 10.1148/radiol.2353041099. View

15.

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G . Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001; 48(2):251-9. PMC: 1728189. DOI: 10.1136/gut.48.2.251. View

16.

Bartolozzi C, Donati F, Cioni D, Procacci C, Morana G, Chiesa A . Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol. 2004; 14(1):14-20. DOI: 10.1007/s00330-003-1966-9. View

17.

McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien P . Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg. 2007; 245(6):923-30. PMC: 1876953. DOI: 10.1097/01.sla.0000251747.80025.b7. View

18.

Fernandez F, Ritter J, Goodwin J, Linehan D, Hawkins W, Strasberg S . Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005; 200(6):845-53. DOI: 10.1016/j.jamcollsurg.2005.01.024. View

19.

Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M . Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010; 256(3):806-16. DOI: 10.1148/radiol.10091334. View

20.

Glimelius B, Pahlman L, Cervantes A . Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v82-6. DOI: 10.1093/annonc/mdq170. View